The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
High drug-loading nanomedicines: progress, current status, and prospects
Open accessAbstract
Drug molecules transformed into nanoparticles or endowed with nanostructures with or without the aid of carrier materials are referred to as "nanomedicines" and can overcome some inherent drawbacks of free drugs, such as poor water solubility, high drug dosage, and short drug half-life in vivo. However, most of the existing nanomedicines possess the drawback of low drug-loading (generally less than 10%) associated with more carrier materials. For intravenous administration, the extensive use of carrier materials might cause systemic toxicity and impose an extra burden of degradation, metabolism, and excretion of the materials for patients. Therefore, on the premise of guaranteeing therapeutic effect and function, reducing or avoiding the use of carrier materials is a promising alternative approach to solve these problems. Recently, high drug-loading nanomedicines, which have a drug-loading content higher than 10%, are attracting increasing interest. According to the fabrication strategies of nanomedicines, high drug-loading nanomedicines are divided into four main classes: nanomedicines with inert porous material as carrier, nanomedicines with drug as part of carrier, carrier-free nanomedicines, and nanomedicines following niche and complex strategies. To date, most of the existing high drug-loading nanomedicines belong to the first class, and few research studies have focused on other classes. In this review, we investigate the research status of high drug-loading nanomedicines and discuss the features of their fabrication strategies and optimum proposal in detail. We also point out deficiencies and developing direction of high drug-loading nanomedicines. We envision that high drug-loading nanomedicines will occupy an important position in the field of drug-delivery systems, and hope that novel perspectives will be proposed for the development of high drug-loading nanomedicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Design and synthesis of an exceptionally stable and highly porous metal-organic framework
Li, H., Eddaoudi, M., O'Keeffe, M., & Yaghi, O. M. (1999) · Nature · doi:10.1038/46248 · Cited by 8,554
Metal-organic framework materials as catalysts
Lee, J., Farha, O. K., Roberts, J., Scheidt, K. A., Nguyen, S. T., & Hupp, J. T. (2009) · Chemical Society Reviews · doi:10.1039/b807080f · Cited by 7,969
A Chromium Terephthalate-Based Solid with Unusually Large Pore Volumes and Surface Area
Férey, G., Mellot-Draznieks, C., Serre, C., Millange, F., Dutour, J., Surblé, S., & Margiolaki, I. (2005) · Science · doi:10.1126/science.1116275 · Cited by 5,430
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Horcajada, P., Chalati, T., Serre, C., Gillet, B., Sebrie, C., Baati, T., Eubank, J. F., Heurtaux, D., Clayette, P., Kreuz, C., et al. (2010) · Nature Materials · doi:10.1038/nmat2608 · Cited by 4,260
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Nanoparticles with Raman Spectroscopic Fingerprints for DNA and RNA Detection
Cao, Y. C., Jin, R., & Mirkin, C. A. (2002) · Science · doi:10.1126/science.297.5586.1536 · Cited by 2,971
Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers☆
SLOWING, I., VIVEROESCOTO, J., WU, C., & LIN, V (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.012 · Cited by 2,653
Cited by
Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery
Majumder, J., & Minko, T. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1828339 · Cited by 348
Biosafety of mesoporous silica nanoparticles; towards clinical translation
Lérida-Viso, A., Estepa-Fernández, A., García-Fernández, A., Martí-Centelles, V., & Martínez-Máñez, R. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115049 · Cited by 279
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
Liu, D., Jin, F., Shu, G., Xu, X., Qi, J., Kang, X., Yu, H., Lu, K., Jiang, S., Han, F., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.034 · Cited by 169
Chen, C., Sun, M., Wang, J., Su, L., Lin, J., & Yan, X. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12163 · Cited by 163
Metadata
- Authors
- Shen, S., Wu, Y., Liu, Y., & Wu, D.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-05
- Volume
- Volume 12
- Pages
- 4085-4109
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2618974892
- Cited by
- 618
- References
- 183
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High drug-loading nanomedicines: progress, current status, and prospects. https://app.cochat.ai/papers/10.2147/ijn.s132780
- The paper
- Shen, S., Wu, Y., Liu, Y., & Wu, D. (2017). High drug-loading nanomedicines: progress, current status, and prospects. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s132780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.